{"transactions":[{"id":758947,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:16:01.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the Reporting Person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in 36 equal monthly installments commencing on June 27, 2026, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":20.44,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001777760-26-000016","document":"wk-form4_1780085758.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000177776026000016/wk-form4_1780085758.xml","form_type":"4"}},{"id":861725,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-04T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":42945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":42945,"derivative":{"exercise_price":7.95,"expiration_date":"2036-02-24","underlying":"Common Stock","underlying_shares":42945},"source":{"system":"sec-edgar","filing":"0001193125-26-091626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000119312526091626/ownership.xml","form_type":"4"}},{"id":861724,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-04T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":11006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":11006,"source":{"system":"sec-edgar","filing":"0001193125-26-091626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000119312526091626/ownership.xml","form_type":"4"}},{"id":1572504,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25100,"price":142.74,"value":3582774.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"These Options vested as to 25% on February 9, 2024, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":187.26,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":25100},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572503,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73250,"price":218.03,"value":15970697.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These Options vested as to 25% on February 16, 2023, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":111.97,"expiration_date":"2032-02-16","underlying":"Common Stock","underlying_shares":73250},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572502,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":66900,"price":198.36,"value":13270284.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"These Options vested as to 25% on February 23, 2022, with the remaining Options to vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":0,"derivative":{"exercise_price":131.64,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":66900},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572501,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":70000,"price":230.28,"value":16119600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":99.72,"expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572500,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":231992,"price":320.8,"value":74423033.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":231992},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572499,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11578,"price":322.73,"value":3736567.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.27,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":11578},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572498,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47817,"price":327.08,"value":15639984.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":47817},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572497,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Restricted Stock Units","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15855,"price":330,"value":5232150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RSUs granted on February 13, 2024 (the \"2024 RSUs\"), each representing a contingent right to receive one share of Common Stock, provided that, at the effective time of the Merger, any 2024 RSUs that were not vested and remained outstanding as of such date were cancelled and converted into the right to receive a cash payment equal to the product of (i) the number of unvested 2024 RSUs outstanding at the effective time of the Merger multiplied by (ii) the Merger Consideration (the \"Cash Award\"). The Cash Award shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15855},"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572496,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9412,"price":330,"value":3105960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1572495,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"officer":true,"officer_title":"President of R&D"}}],"security":"Common Stock","published_at":"2024-03-18T20:30:50.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13977,"price":330,"value":4612410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."}],"balance_after":9412,"source":{"system":"sec-edgar","filing":"0001140361-24-013930","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000114036124013930/form4.xml","form_type":"4"}},{"id":1641050,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Restricted Stock Units","published_at":"2024-02-15T21:42:20.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":15855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date."}],"balance_after":15855,"derivative":{"underlying":"Common Stock","underlying_shares":15855},"source":{"system":"sec-edgar","filing":"0000950170-24-015958","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017024015958/ownership.xml","form_type":"4"}},{"id":1649397,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President of R&D"}}],"security":"Common Stock","published_at":"2024-02-12T22:11:39.000Z","date":"2024-02-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":1011,"price":317.14,"value":320628.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units previously granted to the Reporting Person on February 9, 2023."}],"balance_after":23389,"source":{"system":"sec-edgar","filing":"0000950170-24-013962","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017024013962/ownership.xml","form_type":"4"}},{"id":1916510,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-20","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019."}],"balance_after":231992,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":1916509,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-18","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019."}],"balance_after":240492,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":1916508,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-20","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":200.13,"value":3001950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022."}],"balance_after":24400,"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":1916507,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-20","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":9.2,"value":78200.0,"ownership":{"direct":true},"balance_after":39400,"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":1916506,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-18","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":200.16,"value":6004800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":30900,"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":1916505,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-04-20T22:17:19.000Z","date":"2023-04-18","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":9.2,"value":276000.0,"ownership":{"direct":true},"balance_after":60900,"source":{"system":"sec-edgar","filing":"0000950170-23-013722","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000095017023013722/ownership.xml","form_type":"4"}},{"id":2020129,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2023-02-13T21:33:11.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":25100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":25100,"derivative":{"exercise_price":187.26,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":25100},"source":{"system":"sec-edgar","filing":"0001593968-23-000302","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396823000302/primary_01.xml","form_type":"4"}},{"id":2020128,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-02-13T21:33:11.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":12550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates."}],"balance_after":30900,"source":{"system":"sec-edgar","filing":"0001593968-23-000302","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396823000302/primary_01.xml","form_type":"4"}},{"id":2077705,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-22T21:11:39.000Z","date":"2022-12-21","kind":"exercise","acquired":false,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":47817,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001593968-22-001764","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001764/primary_01.xml","form_type":"4"}},{"id":2077704,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-12-22T21:11:39.000Z","date":"2022-12-21","kind":"exercise","acquired":true,"shares":7100,"price":2.92,"value":20732.0,"ownership":{"direct":true},"balance_after":18350,"source":{"system":"sec-edgar","filing":"0001593968-22-001764","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001764/primary_01.xml","form_type":"4"}},{"id":2098437,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-02T22:00:57.000Z","date":"2022-12-02","kind":"exercise","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":54917,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001593968-22-001691","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001691/primary_01.xml","form_type":"4"}},{"id":2098436,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-12-02T22:00:57.000Z","date":"2022-12-02","kind":"exercise","acquired":false,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 1/30th of the shares underlying the option award on each one month anniversary of the vesting commencement date of August 15, 2018."}],"balance_after":11578,"derivative":{"exercise_price":7.27,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001593968-22-001691","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001691/primary_01.xml","form_type":"4"}},{"id":2098435,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:00:57.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":15000,"price":228.3,"value":3424500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001593968-22-001691","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001691/primary_01.xml","form_type":"4"}},{"id":2098434,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:00:57.000Z","date":"2022-12-02","kind":"exercise","acquired":true,"shares":500,"price":2.92,"value":1460.0,"ownership":{"direct":true},"balance_after":26250,"source":{"system":"sec-edgar","filing":"0001593968-22-001691","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001691/primary_01.xml","form_type":"4"}},{"id":2098433,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:00:57.000Z","date":"2022-12-02","kind":"exercise","acquired":true,"shares":250,"price":7.27,"value":1817.5,"ownership":{"direct":true},"balance_after":25750,"source":{"system":"sec-edgar","filing":"0001593968-22-001691","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001691/primary_01.xml","form_type":"4"}},{"id":2118098,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-11-14T21:21:45.000Z","date":"2022-11-11","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":55417,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001593968-22-001596","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001596/primary_01.xml","form_type":"4"}},{"id":2118097,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-11-14T21:21:45.000Z","date":"2022-11-11","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 1/30th of the shares underlying the option award on each one month anniversary of the vesting commencement date of August 15, 2018."}],"balance_after":11828,"derivative":{"exercise_price":7.27,"expiration_date":"2028-08-08","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001593968-22-001596","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001596/primary_01.xml","form_type":"4"}},{"id":2118096,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-14T21:21:45.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":15000,"price":225.98,"value":3389700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001593968-22-001596","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001596/primary_01.xml","form_type":"4"}},{"id":2118095,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-14T21:21:45.000Z","date":"2022-11-11","kind":"exercise","acquired":true,"shares":1000,"price":2.92,"value":2920.0,"ownership":{"direct":true},"balance_after":40500,"source":{"system":"sec-edgar","filing":"0001593968-22-001596","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001596/primary_01.xml","form_type":"4"}},{"id":2118094,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-14T21:21:45.000Z","date":"2022-11-11","kind":"exercise","acquired":true,"shares":1000,"price":7.27,"value":7270.0,"ownership":{"direct":true},"balance_after":39500,"source":{"system":"sec-edgar","filing":"0001593968-22-001596","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001596/primary_01.xml","form_type":"4"}},{"id":2125797,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-11-03T22:31:31.000Z","date":"2022-11-03","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":56417,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001593968-22-001570","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001570/primary_01.xml","form_type":"4"}},{"id":2125796,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-03T22:31:31.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":15000,"price":225.08,"value":3376200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022."}],"balance_after":38500,"source":{"system":"sec-edgar","filing":"0001593968-22-001570","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001570/primary_01.xml","form_type":"4"}},{"id":2125795,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-11-03T22:31:31.000Z","date":"2022-11-03","kind":"exercise","acquired":true,"shares":2000,"price":2.92,"value":5840.0,"ownership":{"direct":true},"balance_after":53500,"source":{"system":"sec-edgar","filing":"0001593968-22-001570","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822001570/primary_01.xml","form_type":"4"}},{"id":2388713,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2022-02-17T22:14:51.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":73250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates."}],"balance_after":73250,"derivative":{"exercise_price":111.97,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":73250},"source":{"system":"sec-edgar","filing":"0001593968-22-000492","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396822000492/primary_01.xml","form_type":"4"}},{"id":2526503,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":26500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":58417,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":26500},"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526502,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":300,"price":144.54,"value":43362.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.46 to $144.67, inclusive."}],"balance_after":51500,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526501,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":740,"price":143.78,"value":106397.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.35 to $144.24, inclusive."}],"balance_after":51800,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526500,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":787,"price":142.14,"value":111864.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.93 to $142.85, inclusive."}],"balance_after":52540,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526499,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":400,"price":140.74,"value":56296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.55 to $141.18, inclusive."}],"balance_after":53327,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526498,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":500,"price":139.87,"value":69935.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.48 to $140.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (6) to this Form 4."}],"balance_after":53727,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526497,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":100,"price":136.67,"value":13667.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."}],"balance_after":54227,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2526496,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-11-03T20:18:22.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":26500,"price":2.92,"value":77380.0,"ownership":{"direct":true},"balance_after":54327,"source":{"system":"sec-edgar","filing":"0001593968-21-002357","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002357/primary_01.xml","form_type":"4"}},{"id":2549236,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":3029,"price":125.17,"value":379139.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.58, inclusive."}],"balance_after":27827,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549235,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":8774,"price":125.18,"value":1098329.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.69 to $125.62, inclusive."}],"balance_after":30856,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549234,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":1787,"price":124.17,"value":221891.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.65 to $124.64, inclusive."}],"balance_after":39630,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549233,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":1210,"price":123.09,"value":148938.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.64 to $123.64, inclusive."}],"balance_after":41417,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549232,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":400,"price":121.34,"value":48536.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.84 to $121.69, inclusive."}],"balance_after":42627,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549231,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":600,"price":120.13,"value":72078.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.83 to $120.72, inclusive."}],"balance_after":43027,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2549230,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-10-05T20:13:19.000Z","date":"2021-10-01","kind":"sale","acquired":false,"shares":700,"price":118.55,"value":82985.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.20 to $119.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (8) to this Form 4."}],"balance_after":43627,"source":{"system":"sec-edgar","filing":"0001593968-21-002238","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002238/primary_01.xml","form_type":"4"}},{"id":2579499,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:50:08.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":2673,"price":125.51,"value":335488.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $125.00 to $126.00, inclusive."}],"balance_after":44327,"source":{"system":"sec-edgar","filing":"0001593968-21-002085","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002085/primary_01.xml","form_type":"4"}},{"id":2579498,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:50:08.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":500,"price":119.52,"value":59760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $119.23 to $119.97, inclusive."}],"balance_after":47000,"source":{"system":"sec-edgar","filing":"0001593968-21-002085","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002085/primary_01.xml","form_type":"4"}},{"id":2579497,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:50:08.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":3410,"price":118.62,"value":404494.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $118.22 to $119.22, inclusive."}],"balance_after":47500,"source":{"system":"sec-edgar","filing":"0001593968-21-002085","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002085/primary_01.xml","form_type":"4"}},{"id":2579496,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-09-03T21:50:08.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":1590,"price":117.87,"value":187413.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $117.21 to $118.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnotes (2) through (5) to this Form 4."}],"balance_after":50910,"source":{"system":"sec-edgar","filing":"0001593968-21-002085","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821002085/primary_01.xml","form_type":"4"}},{"id":2598080,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-08-18T23:44:10.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vested as to 1/16th of the shares underlying the option award on the vesting commencement date of July 18, 2016 and as to an additional 1/16th of the shares on each three month anniversary thereafter."}],"balance_after":84917,"derivative":{"exercise_price":2.92,"expiration_date":"2026-10-11","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001593968-21-001993","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001993/primary_01.xml","form_type":"4"}},{"id":2598079,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-18T23:44:10.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":100,"price":105.83,"value":10583.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0001593968-21-001993","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001993/primary_01.xml","form_type":"4"}},{"id":2598078,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-18T23:44:10.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":4021,"price":104.14,"value":418746.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.65, inclusive."}],"balance_after":52600,"source":{"system":"sec-edgar","filing":"0001593968-21-001993","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001993/primary_01.xml","form_type":"4"}},{"id":2598077,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-18T23:44:10.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1379,"price":103.15,"value":142243.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.67 to $103.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":56621,"source":{"system":"sec-edgar","filing":"0001593968-21-001993","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001993/primary_01.xml","form_type":"4"}},{"id":2598076,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-08-18T23:44:10.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":12500,"price":2.92,"value":36500.0,"ownership":{"direct":true},"balance_after":58000,"source":{"system":"sec-edgar","filing":"0001593968-21-001993","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001993/primary_01.xml","form_type":"4"}},{"id":2670326,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-14","kind":"exercise","acquired":false,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable in thirty equal monthly installments beginning on March 21, 2019."}],"balance_after":270492,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670325,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-11","kind":"exercise","acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable in thirty equal monthly installments beginning on March 21, 2019."}],"balance_after":278826,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670324,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-10","kind":"exercise","acquired":false,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests and becomes exercisable in thirty equal monthly installments beginning on March 21, 2019."}],"balance_after":287159,"derivative":{"exercise_price":9.2,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670323,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-14","kind":"sale","acquired":false,"shares":8334,"price":131.44,"value":1095420.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670322,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-14","kind":"exercise","acquired":true,"shares":8334,"price":9.2,"value":76672.8,"ownership":{"direct":true},"balance_after":53834,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670321,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-11","kind":"sale","acquired":false,"shares":8333,"price":129.33,"value":1077706.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670320,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-11","kind":"exercise","acquired":true,"shares":8333,"price":9.2,"value":76663.6,"ownership":{"direct":true},"balance_after":53833,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670319,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":13333,"price":123.68,"value":1649025.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2670318,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-06-15T01:13:19.000Z","date":"2021-06-10","kind":"exercise","acquired":true,"shares":13333,"price":9.2,"value":122663.6,"ownership":{"direct":true},"balance_after":58833,"source":{"system":"sec-edgar","filing":"0001593968-21-001617","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001617/primary_01.xml","form_type":"4"}},{"id":2716735,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-05-12T21:29:58.000Z","date":"2021-05-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":300492,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-21-001293","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001293/primary_01.xml","form_type":"4"}},{"id":2716734,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-05-12T21:29:58.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":5000,"price":110.43,"value":552150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-001293","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001293/primary_01.xml","form_type":"4"}},{"id":2716733,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-05-12T21:29:58.000Z","date":"2021-05-10","kind":"exercise","acquired":true,"shares":5000,"price":9.2,"value":46000.0,"ownership":{"direct":true},"balance_after":50500,"source":{"system":"sec-edgar","filing":"0001593968-21-001293","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001293/primary_01.xml","form_type":"4"}},{"id":2749626,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-04-14T20:29:14.000Z","date":"2021-04-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":305492,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-21-001113","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001113/primary_01.xml","form_type":"4"}},{"id":2749625,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-04-14T20:29:14.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":5000,"price":114.22,"value":571100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-001113","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001113/primary_01.xml","form_type":"4"}},{"id":2749624,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-04-14T20:29:14.000Z","date":"2021-04-12","kind":"exercise","acquired":true,"shares":5000,"price":9.2,"value":46000.0,"ownership":{"direct":true},"balance_after":50500,"source":{"system":"sec-edgar","filing":"0001593968-21-001113","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821001113/primary_01.xml","form_type":"4"}},{"id":2792234,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-03-12T21:35:09.000Z","date":"2021-03-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":310492,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-21-000905","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000905/primary_01.xml","form_type":"4"}},{"id":2792233,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-03-12T21:35:09.000Z","date":"2021-03-10","kind":"sale","acquired":false,"shares":5000,"price":118.48,"value":592400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-000905","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000905/primary_01.xml","form_type":"4"}},{"id":2792232,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-03-12T21:35:09.000Z","date":"2021-03-10","kind":"exercise","acquired":true,"shares":5000,"price":9.2,"value":46000.0,"ownership":{"direct":true},"balance_after":50500,"source":{"system":"sec-edgar","filing":"0001593968-21-000905","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000905/primary_01.xml","form_type":"4"}},{"id":2836095,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-02-24T22:00:35.000Z","date":"2021-02-23","kind":"grant","acquired":true,"shares":66900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest on February 23, 2022, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates"}],"balance_after":66900,"derivative":{"exercise_price":131.64,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":66900},"source":{"system":"sec-edgar","filing":"0000899243-21-008032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000089924321008032/doc4.xml","form_type":"4"}},{"id":2863712,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-02-12T21:21:17.000Z","date":"2021-02-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":315492,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-21-000439","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000439/primary_01.xml","form_type":"4"}},{"id":2863711,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-02-12T21:21:17.000Z","date":"2021-02-10","kind":"sale","acquired":false,"shares":5000,"price":114.06,"value":570300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-000439","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000439/primary_01.xml","form_type":"4"}},{"id":2863710,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-02-12T21:21:17.000Z","date":"2021-02-10","kind":"exercise","acquired":true,"shares":5000,"price":9.2,"value":46000.0,"ownership":{"direct":true},"balance_after":50500,"source":{"system":"sec-edgar","filing":"0001593968-21-000439","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000439/primary_01.xml","form_type":"4"}},{"id":2909729,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"exercise","acquired":false,"shares":1428,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":320492,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":1428},"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2909728,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"exercise","acquired":false,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12828,"derivative":{"exercise_price":7.27,"exercise_date":"2018-09-15","expiration_date":"2028-08-09","underlying":"Common Stock","underlying_shares":3572},"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2909727,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":1428,"price":105.11,"value":150097.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2909726,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"exercise","acquired":true,"shares":1428,"price":9.2,"value":13137.6,"ownership":{"direct":true},"balance_after":46928,"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2909725,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"sale","acquired":false,"shares":3572,"price":105.11,"value":375452.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2909724,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-12T21:34:56.000Z","date":"2021-01-11","kind":"exercise","acquired":true,"shares":3572,"price":7.27,"value":25968.44,"ownership":{"direct":true},"balance_after":49072,"source":{"system":"sec-edgar","filing":"0001593968-21-000123","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396821000123/primary_01.xml","form_type":"4"}},{"id":2946792,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"exercise","acquired":false,"shares":1429,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":321920,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":1429},"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946791,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"exercise","acquired":false,"shares":3571,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16400,"derivative":{"exercise_price":7.27,"exercise_date":"2018-09-15","expiration_date":"2028-08-09","underlying":"Common Stock","underlying_shares":3571},"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946790,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-14","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":97417,"derivative":{"exercise_price":2.92,"exercise_date":"2016-07-18","expiration_date":"2026-10-12","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946789,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"sale","acquired":false,"shares":1429,"price":94.82,"value":135497.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946788,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"exercise","acquired":true,"shares":1429,"price":9.2,"value":13146.8,"ownership":{"direct":true},"balance_after":46929,"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946787,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"sale","acquired":false,"shares":3571,"price":94.82,"value":338602.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946786,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-10","kind":"exercise","acquired":true,"shares":3571,"price":7.27,"value":25961.17,"ownership":{"direct":true},"balance_after":49071,"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2946785,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2020-12-14T22:11:32.000Z","date":"2020-12-14","kind":"exercise","acquired":true,"shares":12500,"price":2.92,"value":36500.0,"ownership":{"direct":true},"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001593968-20-002355","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002355/primary_01.xml","form_type":"4"}},{"id":2984103,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2020-11-12T21:24:50.000Z","date":"2020-11-12","kind":"exercise","acquired":false,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":323349,"derivative":{"exercise_price":9.2,"exercise_date":"2019-04-21","expiration_date":"2029-03-21","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001593968-20-002189","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000159396820002189/primary_01.xml","form_type":"4"}}],"next_cursor":"2020-11-12T21:24:50.000000Z,2984103"}